Bioxytran, Inc. (OTCQB:BIXT) reported that its oral antiviral ProLectin‑M achieved statistically significant earlier viral clearance and faster clinical improvement in a randomized, double‑blind, placebo‑controlled Phase 1b/2a study of 39 hospitalized patients with mild‑to‑moderate COVID‑19. The study, conducted in India, evaluated a 16,800 mg/day dose and found that 90 % of patients reached non‑detectable viral shedding by Day 5, compared with 20 % in the placebo arm (p = 0.001). The trial also confirmed a favorable safety profile, with no serious adverse events and no treatment‑related discontinuations.
The Phase 1b/2a results build on earlier work, including a February 2026 Phase 2 trial that reported 100 % viral load elimination by Day 7 and 88 % clearance by Day 3, and a March 2023 study that demonstrated rapid viral clearance through galectin‑3 inhibition. ProLectin‑M’s mechanism—blocking galectins that viruses use for cellular entry—suggests potential broad‑spectrum activity against influenza, RSV, and other respiratory pathogens.
"We believe an oral, well‑tolerated antiviral with a differentiated mechanism could address important gaps in current treatment approaches, particularly in early‑stage respiratory infections," said Dr. Leslie Ajayi, Chief Medical Officer. "These findings provide confirmation of an early clinical trials antiviral effect and support further evaluation of ProLectin‑M's novel galectin‑targeting mechanism." CEO David Platt added, "The clinical trials results are opening a new horizon for a new generation of safe anti‑viral drugs. We believe the consistency of the observed activity supports continued clinical development of this oral therapeutic approach."
Bioxytran’s galectin‑1 inhibition strategy positions the company to pursue a first‑line therapy for COVID‑19 and other viral infections. The company maintains an active U.S. FDA Investigational New Drug application for ProLectin‑M and is concurrently developing BXT‑25, a universal oxygen carrier for stroke and neurodegenerative diseases. While the company’s financials remain modest—net losses of $283 k in Q3 2025 and a market capitalization of roughly $4.5 million as of 2022—the positive clinical data strengthen its pipeline and may attract future investment or partnership opportunities.
The Phase 1b/2a milestone underscores ProLectin‑M’s potential as a broad‑spectrum antiviral and validates Bioxytran’s unique approach to viral entry inhibition. The favorable safety profile and rapid viral clearance support progression to larger, phase 3 studies that could establish the drug as a first‑line oral therapy for COVID‑19 and potentially other respiratory viruses. The company’s continued focus on clinical development, coupled with its existing IND status, positions it to capitalize on unmet medical needs in the antiviral market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.